A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With IgAN, LN, or C3G
Latest Information Update: 23 Apr 2025
At a glance
- Drugs ADX-097 (Primary)
- Indications IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis
- Focus Adverse reactions
- Sponsors Q32 Bio
Most Recent Events
- 20 Apr 2025 Status changed from discontinued to withdrawn prior to enrolment and the study was closed prior to enrolling any patients.
- 10 Feb 2025 Status changed from recruiting to discontinued.
- 19 Dec 2024 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.